Mumbai, Jan. 30 -- Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Pimavanserin, marketed globally as NUPLAZID, has become a preferred treatment in the US antipsychotic segment.

In a recent update, Acadia Pharmaceuticals announced that NUPLAZID, along with its other brand DAYBUE, is projected to generate more than $1 billion in net sales in 2025.

The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product's availability in the domestic market.

Anil Jain, managing director, Bajaj Healthcare, said: "The approval marks a major milestone for Bajaj Healthcare.

Th...